These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 16890327

  • 21. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
    Wang F, Ma Z, Li Y, Zhu S, Xiao Z, Zhang H, Wang Y.
    J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
    [Abstract] [Full Text] [Related]

  • 22. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
    Cho YS, Borland M, Brain C, Chen CH, Cheng H, Chopra R, Chung K, Groarke J, He G, Hou Y, Kim S, Kovats S, Lu Y, O'Reilly M, Shen J, Smith T, Trakshel G, Vögtle M, Xu M, Xu M, Sung MJ.
    J Med Chem; 2010 Nov 25; 53(22):7938-57. PubMed ID: 21038853
    [Abstract] [Full Text] [Related]

  • 23. Computational evaluation of some indenopyrazole derivatives as anticancer compounds; application of QSAR and docking methodologies.
    Shahlaei M, Fassihi A, Saghaie L, Arkan E, Madadkar-Sobhani A, Pourhossein A.
    J Enzyme Inhib Med Chem; 2013 Feb 25; 28(1):16-32. PubMed ID: 21999517
    [Abstract] [Full Text] [Related]

  • 24. Why pyridine containing pyrido[2,3-d]pyrimidin-7-ones selectively inhibit CDK4 than CDK2: insights from molecular dynamics simulation.
    Mascarenhas NM, Bhattacharyya D, Ghoshal N.
    J Mol Graph Model; 2010 Apr 25; 28(7):695-706. PubMed ID: 20153225
    [Abstract] [Full Text] [Related]

  • 25. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.
    J Med Chem; 2006 Nov 02; 49(22):6500-9. PubMed ID: 17064068
    [Abstract] [Full Text] [Related]

  • 26. 3D-QSAR studies of pyruvate dehydrogenase kinase inhibitors based on a divide and conquer strategy.
    Aboye TL, Sobhia ME, Bharatam PV.
    Bioorg Med Chem; 2004 May 15; 12(10):2709-15. PubMed ID: 15110852
    [Abstract] [Full Text] [Related]

  • 27. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y, Gao W, Li F, Wang J, Zhang J, Yang Y, Zhang S, Yang L.
    Mol Biosyst; 2013 Sep 15; 9(9):2266-81. PubMed ID: 23864105
    [Abstract] [Full Text] [Related]

  • 28. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
    Moon MJ, Lee SK, Lee JW, Song WK, Kim SW, Kim JI, Cho C, Choi SJ, Kim YC.
    Bioorg Med Chem; 2006 Jan 01; 14(1):237-46. PubMed ID: 16182537
    [Abstract] [Full Text] [Related]

  • 29. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM.
    Chem Biol; 2004 Apr 01; 11(4):525-34. PubMed ID: 15123247
    [Abstract] [Full Text] [Related]

  • 30. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
    Baltus CB, Jorda R, Marot C, Berka K, Bazgier V, Kryštof V, Prié G, Viaud-Massuard MC.
    Eur J Med Chem; 2016 Jan 27; 108():701-719. PubMed ID: 26741853
    [Abstract] [Full Text] [Related]

  • 31. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ, Lei M, Lu AJ, Zhao X, Yin XJ, Gao QZ.
    Eur J Med Chem; 2009 Apr 27; 44(4):1486-99. PubMed ID: 18771818
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
    Mahale S, Aubry C, Jenkins PR, Maréchal JD, Sutcliffe MJ, Chaudhuri B.
    Bioorg Chem; 2006 Oct 27; 34(5):287-97. PubMed ID: 16904725
    [Abstract] [Full Text] [Related]

  • 33. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
    Vadivelan S, Sinha BN, Irudayam SJ, Jagarlapudi SA.
    J Chem Inf Model; 2007 Oct 27; 47(4):1526-35. PubMed ID: 17523616
    [Abstract] [Full Text] [Related]

  • 34. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD, Hamza A, Liu J, Zhan CG.
    J Chem Inf Model; 2008 Sep 27; 48(9):1760-72. PubMed ID: 18717540
    [Abstract] [Full Text] [Related]

  • 35. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S, Wood G, Meades C, Griffiths G, Midgley C, McNae I, McInnes C, Anderson S, Jackson W, Mezna M, Yuill R, Walkinshaw M, Fischer PM.
    Bioorg Med Chem Lett; 2004 Aug 16; 14(16):4237-40. PubMed ID: 15261277
    [Abstract] [Full Text] [Related]

  • 36. Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
    Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, Keertikar K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann TO, Hruza A, Madison V, Nomeir AA, Wang Y, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6220-3. PubMed ID: 17904841
    [Abstract] [Full Text] [Related]

  • 37. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
    Pevarello P, Fancelli D, Vulpetti A, Amici R, Villa M, Pittalà V, Vianello P, Cameron A, Ciomei M, Mercurio C, Bischoff JR, Roletto F, Varasi M, Brasca MG.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):1084-90. PubMed ID: 16290148
    [Abstract] [Full Text] [Related]

  • 38. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S, Lilly M, Brown ML.
    Bioorg Med Chem; 2007 Oct 01; 15(19):6463-73. PubMed ID: 17637507
    [Abstract] [Full Text] [Related]

  • 39. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
    Sciabola S, Stanton RV, Wittkopp S, Wildman S, Moshinsky D, Potluri S, Xi H.
    J Chem Inf Model; 2008 Sep 01; 48(9):1851-67. PubMed ID: 18717582
    [Abstract] [Full Text] [Related]

  • 40. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF, Cacho M, García ML, Mayoral EP, López B, de Pascual-Teresa B, Ramos A, Acero N, Llinares F, Muñoz-Mingarro D, Lozach O, Meijer L.
    J Med Chem; 2005 Nov 03; 48(22):6843-54. PubMed ID: 16250643
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.